SF Healthcare Week: The Co-Founder and CEO of Kardigan talks about this week's $300M series A financing to do precision medicine for cardiovascular disease

blonca9
Jan 16
1 min read

Tassos Gianakakos describes the round and the investors who participated in it, and hints at the personalized, biomarker driven approach that Kardigan will have to developing medicines that benefit a wider percentage of the population than today's 'one size fits all' approach to this area.

Recent Posts

See All

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

SF Healthcare Week: The Co-Founder and CEO of Kardigan talks about this week's $300M series A financing to do precision medicine for cardiovascular disease

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight